R
Russell P. Rother
Researcher at Alexion Pharmaceuticals
Publications - 129
Citations - 10458
Russell P. Rother is an academic researcher from Alexion Pharmaceuticals. The author has contributed to research in topics: Eculizumab & Paroxysmal nocturnal hemoglobinuria. The author has an hindex of 42, co-authored 129 publications receiving 9599 citations. Previous affiliations of Russell P. Rother include Leeds Teaching Hospitals NHS Trust & University of Glasgow.
Papers
More filters
Journal ArticleDOI
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.
TL;DR: A growing body of evidence supports the existence of a novel mechanism of human disease, namely, hemolysis-associated smooth muscle dystonia, vasculopathy, and endothelial dysfunction.
Journal ArticleDOI
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Neal S. Young,Jörg Schubert,Robert A. Brodsky,Gérard Socié,Petra Muus,Alexander Röth,Jeff Szer,Modupe O. Elebute,Ryotaro Nakamura,Paul Browne,Antonio M. Risitano,Anita Hill,Hubert Schrezenmeier,Chieh Lin Fu,Jaroslaw P. Maciejewski,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother,Lucio Luzzatto +19 more
TL;DR: Eculizumab is an effective therapy for PNH and Clinically significant improvements were found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
Journal ArticleDOI
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
TL;DR: The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Journal ArticleDOI
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Claire Hall,Judith C. W. Marsh,Modupe O. Elebute,Michael P Bombara,Beth E. Petro,Matthew J. Cullen,Stephen J. Richards,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother +10 more
TL;DR: This antibody against terminal complement protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an associated improvement in the quality of life in patients with PNH.
Journal ArticleDOI
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Kenneth I. Ataga,Abdullah Kutlar,Julie Kanter,Darla K. Liles,Rodolfo D. Cançado,Joao Ricardo Friedrisch,Troy H. Guthrie,Jennifer Knight-Madden,Ofelia A. Alvarez,Victor R. Gordeuk,Sandra Fátima Menosi Gualandro,Marina Pereira Colella,Wally R. Smith,Scott A. Rollins,Jonathan W. Stocker,Russell P. Rother +15 more
TL;DR: In patients with Sickle cell disease, crizanlizumab therapy resulted in a significantly lower rate of sickle cell–related pain crises than placebo and was associated with a low incidence of adverse events.